Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adalimumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44337   clinical trials with a EudraCT protocol, of which   7367   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    468 result(s) found for: Adalimumab. Displaying page 23 of 24.
    «« First « Previous 16  17  18  19  20  21  22  23  24  Next»
    EudraCT Number: 2016-000642-62 Sponsor Protocol Number: M14-675 Start Date*: 2019-06-13
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: M14-675, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulc...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) LV (Completed) PT (Completed) FI (Completed) DE (Completed) GR (Completed) SE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) CZ (Completed) LT (Completed) IE (Completed) BE (Completed) HU (Completed) ES (Completed) SK (Completed) PL (Completed) FR (Completed) HR (Completed) NO (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-003703-22 Sponsor Protocol Number: P2-IMU-838-UC Start Date*: 2018-05-03
    Sponsor Name:Immunic AG
    Full Title: A phase 2, multicenter, randomized, double-blind, placebo controlled, dose-finding study to evaluate the efficacy and safety of IMU 838 for induction and maintenance therapy in moderate-to-severe u...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) NL (Completed) PL (Completed) PT (Completed) HR (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-005019-30 Sponsor Protocol Number: IM047-023 Start Date*: 2022-12-09
    Sponsor Name:Celgene International II Sarl
    Full Title: A Phase 2/3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Participants with Moderately...
    Medical condition: Moderately to Severely Active Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-003577-27 Sponsor Protocol Number: A6631007 Start Date*: 2006-12-01
    Sponsor Name:Pfizer Luxembourg SARL Branch Office Estonia
    Full Title: A 12-WEEK, PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF PH-797804, ADMINISTERED ORALLY ONCE DAILY IN SUBJECTS WITH ACTIVE...
    Medical condition: Treatment of rheumatoid arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-005771-39 Sponsor Protocol Number: RVLO221-02 Start Date*: 2023-03-16
    Sponsor Name:Revolo Biotherapeutics Ltd
    Full Title: A Phase 2, randomised, double-blind, placebo-controlled, dose escalation study to investigate the effects of IRL201805 in participants with moderately to severely active rheumatoid arthritis
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022207-22 Sponsor Protocol Number: H9B-MC-BCDV Start Date*: 2011-06-08
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an ...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Completed) GR (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002500-24 Sponsor Protocol Number: AOSD.2014.001 Start Date*: 2015-02-19
    Sponsor Name:AB2 Bio Ltd.
    Full Title: Open-label, multicenter, dose-escalating phase II study to investigate the safety, tolerability, and early signs of efficacy of subcutaneous administrations of Tadekinig alfa (IL-18BP) in patients ...
    Medical condition: Adult -onset Still’s Disease (AoSD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10064056 Still's disease adult onset PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003956-18 Sponsor Protocol Number: PREVENT-JIA Start Date*: 2014-04-29
    Sponsor Name:University Medical Center Utrecht
    Full Title: Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis (JIA)
    Medical condition: juvenile idiopathic arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004859 10059177 Juvenile arthritis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-005151-83 Sponsor Protocol Number: MUCUS Start Date*: 2018-10-26
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: INDUCTION AND MAINTENANCE OF MUCOSAL HEALING IN CROHN’S DISEASE WITH USTEKINUMAB IN CLINICAL PRACTICE
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005303-39 Sponsor Protocol Number: M20-466 Start Date*: 2021-08-31
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to ...
    Medical condition: Moderate to Severe Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) SK (Completed) NL (Completed) CZ (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003913-21 Sponsor Protocol Number: NL78575.018.21 Start Date*: 2022-07-20
    Sponsor Name:Amsterdam UMC
    Full Title: A Prospective, Open-label Pilot Study to Evaluate Effector mechanisms of Hyperbaric Oxygen Therapy in Patients with Moderate-to-Severe Ulcerative Colitis: The PARADOX study
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    20.1 100000004856 10066678 Acute ulcerative colitis LLT
    22.0 100000004856 10082448 Ulcerative colitis relapse LLT
    20.0 10042613 - Surgical and medical procedures 10057480 Hyperbaric oxygen therapy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-011593-15 Sponsor Protocol Number: WA19977 Start Date*: 2009-08-20
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A 24 week randomized double-blind, placebo controlled withdrawal trial with a 16 week open label lead-in phase, and 64 week open label follow-up, to evaluate the efficacy and safety of tocilizumab ...
    Medical condition: Polyarticular-course juvenile idiopathic arthritis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed) ES (Completed) BE (Completed) NL (Not Authorised) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-001925-18 Sponsor Protocol Number: GED-0301-CD-002 Start Date*: 2016-02-24
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of mongersen (GED-0301) for the treatment of subjects with active Crohn’s disease.
    Medical condition: Active Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000016693 10021315 Ileitis terminal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Completed) SK (Completed) LV (Prematurely Ended) EE (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) HU (Completed) CZ (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) BE (Completed) NO (Completed) BG (Prematurely Ended) GR (Completed) HR (Prematurely Ended) FI (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001555-69 Sponsor Protocol Number: 4083-002 Start Date*: 2016-01-15
    Sponsor Name:Kyowa Kirin Pharmaceutical Development, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction Therapy) and Long-term Extension Therapy of an Anti-OX40 Monoclonal Antibody (KHK4083) ...
    Medical condition: Moderately Active Ulcerative Colitis, defined as: •Total Mayo Clinic score of 4 to 9 (range: 0 to 12, with higher scores indicating more disease activity); •Endoscopy subscore (mMES determined by ...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-002308-11 Sponsor Protocol Number: IM047-001 Start Date*: 2021-12-22
    Sponsor Name:Celgene International II Sàrl
    Full Title: A phase 2/3, multicenter, randomized, double-blind study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of oral ozanimod (RPC1063) in pediatric subjects with moderately to ...
    Medical condition: Moderately to Severely Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000435-33 Sponsor Protocol Number: NP25737 Start Date*: 2015-08-07
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A phase I pharmacokinetic and safety study of tocilizumab (TCZ) in patients less than 2 years old with active systemic juvenile idiopathic arthritis (sJIA)
    Medical condition: Systemic Juvenile Idiopathic Arthritis (sJIA)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) BE (Completed) ES (Completed) PL (Completed) GB (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-021184-32 Sponsor Protocol Number: GP13-201/GPN013A2301 Start Date*: 2010-11-30
    Sponsor Name:Hexal AG
    Full Title: A randomized, double-blind, controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of GP2013 and rituximab in patients with rheumatoid arthritis refractory or intolera...
    Medical condition: Refractory rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed) AT (Completed) IT (Completed) BE (Completed) EE (Completed) HU (Completed) PL (Completed) BG (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002857-32 Sponsor Protocol Number: GLPG0634-CL-211 Start Date*: 2014-02-20
    Sponsor Name:Galapagos NV
    Full Title: Double-Blind, Randomized, Placebo-Controlled, Multi Centre Study to Investigate the Efficacy and Safety of GLPG0634 in Subjects With Active Crohn’s Disease With Evidence of Mucosal Ulceration
    Medical condition: Crohn’s Disease With Evidence of Mucosal Ulceration
    Disease: Version SOC Term Classification Code Term Level
    18.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) GB (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-002804-42 Sponsor Protocol Number: M-14745-42 Start Date*: 2019-11-27
    Sponsor Name:Almirall S.A.
    Full Title: An international, multicentre, open label, interventional phase IV clinical study to investigate the efficacy and safety of tildrakizumab 100 mg in patients with moderate-to-severe chronic plaque p...
    Medical condition: Moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003985-15 Sponsor Protocol Number: APD334-301 Start Date*: 2019-06-21
    Sponsor Name:Arena Pharmaceuticals Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    20.1 100000004856 10045366 Ulcerative colitis, unspecified LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) DE (Completed) LV (Completed) AT (Completed) NL (Completed) LT (Completed) PT (Completed) FR (Completed) EE (Completed) HU (Completed) DK (Completed) CZ (Completed) PL (Completed) BG (Completed) ES (Ongoing) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 16  17  18  19  20  21  22  23  24  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 07:26:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA